- Home
- ADPT vs NEA Comparison
ADPT vs NEA Comparison
Compare ADPT & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | NEA |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ADPT | NEA |
|---|---|---|
| Price | $25.31 | $11.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $17.78 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 854.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $10.76 |
| 52 Week High | $26.87 | $11.90 |
Technical Indicators
Market Signals| Indicator | ADPT | NEA |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 45.84 |
| Support Level | $23.92 | $11.16 |
| Resistance Level | $26.16 | $11.67 |
| Average True Range (ATR) | 1.01 | 0.07 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 62.71 | 43.37 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.